BC Week In Review | Oct 20, 2014
Financial News

DiaGenic completes private placement

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Date completed: 2014-10-10   Type: Private placement   Raised: NOK35 million ($5.4 million)   Shares: 53.8 million   Price: NOK0.65   Shares after offering: 285.1 million...
BC Week In Review | Oct 20, 2014
Financial News

DiaGenic proposes rights offering

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Date announced: 2014-09-08   Type: Rights offering   To be raised: NOK35 million ($5.4 million)   Shares: 53.8 million   Price: NOK0.65   Shares outstanding prior:...
BC Week In Review | Mar 24, 2014
Company News

DiaGenic management update

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Hired: Lars Christian Stugaard as acting CEO, effective April 1, while remaining CEO of Strata Marine & Offshore A/S  ...
BC Week In Review | Feb 10, 2014
Company News

DiaGenic management update

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Transitioned: CFO Ruben Ekbraten to acting CEO  ...
BC Week In Review | Jan 27, 2014
Financial News

DiaGenic proposes rights offering

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Date announced: 1/22/14   Type: Rights offering   To be raised: NOK50 million ($8.1 million)   Shares: TBD   Price: NOK0.50   Underwriter: Arctic Securities  ...
BioCentury | Jan 6, 2014
Finance

4Q Stock Wrap-Up: All's well that ends well

Although two segments lost ground in 4Q13, all of biotech's market cap groups finished 2013 in the black. Large caps valued at more than $5 billion led the way in the fourth quarter, tacking on...
BC Week In Review | Nov 4, 2013
Clinical News

MCItect: Clinical trial data

Data from 157 patients in a U.S. and European calibration study showed that MCItect had 75% total prediction accuracy for detecting patients converting to AD within 2 years, with 75% sensitivity and 73% specificity. MCItect...
BC Week In Review | Nov 4, 2013
Company News

DiaGenic diagnostic news

Diagnostic company DiaGenic received a request from shareholders Corona Maritime A/S and Tycoon Industrier A/S to convene an extraordinary general meeting to address the composition of the board. DiaGenic did not disclose details regarding the...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Sep 2, 2013
Company News

DiaGenic diagnostic news

DiaGenic said it will reduce headcount to reduce costs. DiaGenic said the cost reduction program is focused on shorter-term asset value development while maximizing the company's flexibility for longer-term corporate development. The company expects the...
Items per page:
1 - 10 of 40
BC Week In Review | Oct 20, 2014
Financial News

DiaGenic completes private placement

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Date completed: 2014-10-10   Type: Private placement   Raised: NOK35 million ($5.4 million)   Shares: 53.8 million   Price: NOK0.65   Shares after offering: 285.1 million...
BC Week In Review | Oct 20, 2014
Financial News

DiaGenic proposes rights offering

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Date announced: 2014-09-08   Type: Rights offering   To be raised: NOK35 million ($5.4 million)   Shares: 53.8 million   Price: NOK0.65   Shares outstanding prior:...
BC Week In Review | Mar 24, 2014
Company News

DiaGenic management update

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Hired: Lars Christian Stugaard as acting CEO, effective April 1, while remaining CEO of Strata Marine & Offshore A/S  ...
BC Week In Review | Feb 10, 2014
Company News

DiaGenic management update

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Transitioned: CFO Ruben Ekbraten to acting CEO  ...
BC Week In Review | Jan 27, 2014
Financial News

DiaGenic proposes rights offering

DiaGenic ASA (OSE:DIAG), Oslo, Norway   Business: Diagnostic   Date announced: 1/22/14   Type: Rights offering   To be raised: NOK50 million ($8.1 million)   Shares: TBD   Price: NOK0.50   Underwriter: Arctic Securities  ...
BioCentury | Jan 6, 2014
Finance

4Q Stock Wrap-Up: All's well that ends well

Although two segments lost ground in 4Q13, all of biotech's market cap groups finished 2013 in the black. Large caps valued at more than $5 billion led the way in the fourth quarter, tacking on...
BC Week In Review | Nov 4, 2013
Clinical News

MCItect: Clinical trial data

Data from 157 patients in a U.S. and European calibration study showed that MCItect had 75% total prediction accuracy for detecting patients converting to AD within 2 years, with 75% sensitivity and 73% specificity. MCItect...
BC Week In Review | Nov 4, 2013
Company News

DiaGenic diagnostic news

Diagnostic company DiaGenic received a request from shareholders Corona Maritime A/S and Tycoon Industrier A/S to convene an extraordinary general meeting to address the composition of the board. DiaGenic did not disclose details regarding the...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

For the second time this year, all market cap segments closed the quarter in the black. Large caps valued at $5 billion and above gained ground for the fifth consecutive quarter. They added 12%, and...
BC Week In Review | Sep 2, 2013
Company News

DiaGenic diagnostic news

DiaGenic said it will reduce headcount to reduce costs. DiaGenic said the cost reduction program is focused on shorter-term asset value development while maximizing the company's flexibility for longer-term corporate development. The company expects the...
Items per page:
1 - 10 of 40